Last checked at 30 Nov 2016 14:16
RNS
For release: 30 November 2016
genedrive plc ("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held in Manchester today, all resolutions proposed were duly passed.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.
genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.
Further details can be found at: www.genedriveplc.com and www.genedrive.com